Home > Share Market > Stocks > Transgene biotek > Financial Statements > Key Financial Ratios

Transgene biotek Financial Statements

Ratio Analysis

  • Tabular Data
  • Graph
  • Consolidated
  • Standalone
Y/e 31 Mar Mar-2021 Mar-2020 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth 4,642 (97) (58) 54.70
Op profit growth (39) (59) (18) 126
EBIT growth (3.90) 129 (76) (9.50)
Net profit growth (4.80) 70.30 (68) (7.80)
Profitability ratios (%)        
OPM (311) (24,156) (1,781) (912)
EBIT margin (5,997) (295,958) (3,911) (6,919)
Net profit margin (6,154) (306,602) (5,445) (7,072)
RoCE (27) (20) (6.70) (15)
RoNW (9.50) (6.40) (2.90) (4.30)
RoA (6.80) (5.20) (2.30) (3.80)
Per share ratios ()        
EPS (1.40) (1.50) -- --
Dividend per share -- -- -- --
Cash EPS (2.70) (2.80) (2.20) (4.90)
Book value per share 2.94 4.31 6.92 7.77
Valuation ratios        
P/E (3.30) (2.10) -- --
P/CEPS (1.70) (1.10) (1) (0.40)
P/B 1.56 0.70 0.30 0.23
EV/EBIDTA (177) (48) 4.86 (16)
Payout (%)        
Dividend payout -- -- -- --
Tax payout -- -- 13.90 --
Liquidity ratios        
Debtor days 21.50 1,021 30.90 1,072
Inventory days 64.60 4,083 170 91
Creditor days (162) (196) (89) (89)
Leverage ratios        
Interest coverage 38.20 27.80 4.50 45.20
Net debt / equity 0.51 0.31 0.19 0.27
Net debt / op. profit (21) (12) (4.60) (6.20)
Cost breakup ()        
Material costs (36) (414) (41) --
Employee costs (145) (8,098) (277) (197)
Other costs (230) (15,744) (1,562) (815)

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000